{"transactions":[{"id":3775422,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":1,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":2,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series C Preferred Stock","published_at":"2018-11-02T19:51:37.000Z","date":"2018-11-02","kind":"exercise","acquired":false,"shares":308155,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By NeoMed Innovation V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The C preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The C preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The C preferred stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by NeoMed Innovation V, L.P. (\"NeoMed\"). NeoMed Innovation V Limited is the general partner of NeoMed and has voting and dispositive power over the shares held by NeoMed. Erik Amble, Ph.D., who is a member of the Issuer's board of directors, is a director of NeoMed Innovation V Limited, and may be deemed to have voting and dispositive power over the shares held by NeoMed. Mr. Amble disclaims beneficial ownership of these securities and this report shall not be deemed an admission that Mr. Amble is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":369786},"source":{"system":"sec-edgar","filing":"0000899243-18-028110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000089924318028110/doc4.xml","form_type":"4"}},{"id":3775421,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":1,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":2,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series B-2 Preferred Stock","published_at":"2018-11-02T19:51:37.000Z","date":"2018-11-02","kind":"exercise","acquired":false,"shares":203125,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By NeoMed Innovation V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series B-2 preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The B-2 preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series B-2 preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The B-2 preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series B-2 preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The B-2 preferred stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by NeoMed Innovation V, L.P. (\"NeoMed\"). NeoMed Innovation V Limited is the general partner of NeoMed and has voting and dispositive power over the shares held by NeoMed. Erik Amble, Ph.D., who is a member of the Issuer's board of directors, is a director of NeoMed Innovation V Limited, and may be deemed to have voting and dispositive power over the shares held by NeoMed. Mr. Amble disclaims beneficial ownership of these securities and this report shall not be deemed an admission that Mr. Amble is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":243750},"source":{"system":"sec-edgar","filing":"0000899243-18-028110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000089924318028110/doc4.xml","form_type":"4"}},{"id":3775420,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":1,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":2,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series B-1 Preferred Stock","published_at":"2018-11-02T19:51:37.000Z","date":"2018-11-02","kind":"exercise","acquired":false,"shares":379675,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By NeoMed Innovation V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series B-1 preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The B-1 preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series B-1 preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The B-1 preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series B-1 preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The B-1 preferred stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by NeoMed Innovation V, L.P. (\"NeoMed\"). NeoMed Innovation V Limited is the general partner of NeoMed and has voting and dispositive power over the shares held by NeoMed. Erik Amble, Ph.D., who is a member of the Issuer's board of directors, is a director of NeoMed Innovation V Limited, and may be deemed to have voting and dispositive power over the shares held by NeoMed. Mr. Amble disclaims beneficial ownership of these securities and this report shall not be deemed an admission that Mr. Amble is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":455610},"source":{"system":"sec-edgar","filing":"0000899243-18-028110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000089924318028110/doc4.xml","form_type":"4"}},{"id":3775419,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":1,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":2,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series A Preferred Stock","published_at":"2018-11-02T19:51:37.000Z","date":"2018-11-02","kind":"exercise","acquired":false,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By NeoMed Innovation V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series A preferred stock automatically converted into 2.31660 shares of the Issuer's common stock. The A preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series A preferred stock automatically converted into 2.31660 shares of the Issuer's common stock. The A preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series A preferred stock automatically converted into 2.31660 shares of the Issuer's common stock. The A preferred stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by NeoMed Innovation V, L.P. (\"NeoMed\"). NeoMed Innovation V Limited is the general partner of NeoMed and has voting and dispositive power over the shares held by NeoMed. Erik Amble, Ph.D., who is a member of the Issuer's board of directors, is a director of NeoMed Innovation V Limited, and may be deemed to have voting and dispositive power over the shares held by NeoMed. Mr. Amble disclaims beneficial ownership of these securities and this report shall not be deemed an admission that Mr. Amble is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":451738},"source":{"system":"sec-edgar","filing":"0000899243-18-028110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000089924318028110/doc4.xml","form_type":"4"}},{"id":3775418,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":1,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":2,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2018-11-02T19:51:37.000Z","date":"2018-11-02","kind":"exercise","acquired":true,"shares":369786,"ownership":{"direct":false,"nature":"By NeoMed Innovation V, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The C preferred stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by NeoMed Innovation V, L.P. (\"NeoMed\"). NeoMed Innovation V Limited is the general partner of NeoMed and has voting and dispositive power over the shares held by NeoMed. Erik Amble, Ph.D., who is a member of the Issuer's board of directors, is a director of NeoMed Innovation V Limited, and may be deemed to have voting and dispositive power over the shares held by NeoMed. Mr. Amble disclaims beneficial ownership of these securities and this report shall not be deemed an admission that Mr. Amble is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his respective pecuniary interest therein."}],"balance_after":1520884,"source":{"system":"sec-edgar","filing":"0000899243-18-028110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000089924318028110/doc4.xml","form_type":"4"}},{"id":3775417,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":1,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":2,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2018-11-02T19:51:37.000Z","date":"2018-11-02","kind":"exercise","acquired":true,"shares":243750,"ownership":{"direct":false,"nature":"By NeoMed Innovation V, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series B-2 preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The B-2 preferred stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by NeoMed Innovation V, L.P. (\"NeoMed\"). NeoMed Innovation V Limited is the general partner of NeoMed and has voting and dispositive power over the shares held by NeoMed. Erik Amble, Ph.D., who is a member of the Issuer's board of directors, is a director of NeoMed Innovation V Limited, and may be deemed to have voting and dispositive power over the shares held by NeoMed. Mr. Amble disclaims beneficial ownership of these securities and this report shall not be deemed an admission that Mr. Amble is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his respective pecuniary interest therein."}],"balance_after":1151098,"source":{"system":"sec-edgar","filing":"0000899243-18-028110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000089924318028110/doc4.xml","form_type":"4"}},{"id":3775416,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":1,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":2,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2018-11-02T19:51:37.000Z","date":"2018-11-02","kind":"exercise","acquired":true,"shares":455610,"ownership":{"direct":false,"nature":"By NeoMed Innovation V, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series B-1 preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The B-1 preferred stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by NeoMed Innovation V, L.P. (\"NeoMed\"). NeoMed Innovation V Limited is the general partner of NeoMed and has voting and dispositive power over the shares held by NeoMed. Erik Amble, Ph.D., who is a member of the Issuer's board of directors, is a director of NeoMed Innovation V Limited, and may be deemed to have voting and dispositive power over the shares held by NeoMed. Mr. Amble disclaims beneficial ownership of these securities and this report shall not be deemed an admission that Mr. Amble is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his respective pecuniary interest therein."}],"balance_after":907348,"source":{"system":"sec-edgar","filing":"0000899243-18-028110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000089924318028110/doc4.xml","form_type":"4"}},{"id":3775415,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":1,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":2,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2018-11-02T19:51:37.000Z","date":"2018-11-02","kind":"exercise","acquired":true,"shares":451738,"ownership":{"direct":false,"nature":"By NeoMed Innovation V, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series A preferred stock automatically converted into 2.31660 shares of the Issuer's common stock. The A preferred stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by NeoMed Innovation V, L.P. (\"NeoMed\"). NeoMed Innovation V Limited is the general partner of NeoMed and has voting and dispositive power over the shares held by NeoMed. Erik Amble, Ph.D., who is a member of the Issuer's board of directors, is a director of NeoMed Innovation V Limited, and may be deemed to have voting and dispositive power over the shares held by NeoMed. Mr. Amble disclaims beneficial ownership of these securities and this report shall not be deemed an admission that Mr. Amble is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his respective pecuniary interest therein."}],"balance_after":451738,"source":{"system":"sec-edgar","filing":"0000899243-18-028110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000089924318028110/doc4.xml","form_type":"4"}},{"id":4155939,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":1,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171724,"kind":"organization","name":"NeoMed Management (Jersey) Ltd","position":2,"cik":"0001722665","reported_name":"NeoMed Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":3,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2017-11-20T23:15:22.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":952497,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":279079},"source":{"system":"sec-edgar","filing":"0000899243-17-027028","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924317027028/doc4.xml","form_type":"4"}},{"id":4155938,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":1,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171724,"kind":"organization","name":"NeoMed Management (Jersey) Ltd","position":2,"cik":"0001722665","reported_name":"NeoMed Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":3,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2017-11-20T23:15:22.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":84040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":41878},"source":{"system":"sec-edgar","filing":"0000899243-17-027028","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924317027028/doc4.xml","form_type":"4"}},{"id":4155937,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":1,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171724,"kind":"organization","name":"NeoMed Management (Jersey) Ltd","position":2,"cik":"0001722665","reported_name":"NeoMed Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":3,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2017-11-20T23:15:22.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":552487,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":246682},"source":{"system":"sec-edgar","filing":"0000899243-17-027028","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924317027028/doc4.xml","form_type":"4"}},{"id":4155936,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":1,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171724,"kind":"organization","name":"NeoMed Management (Jersey) Ltd","position":2,"cik":"0001722665","reported_name":"NeoMed Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":3,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T23:15:22.000Z","date":"2017-11-20","kind":"purchase","acquired":true,"shares":300000,"price":10,"value":3000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":867639,"source":{"system":"sec-edgar","filing":"0000899243-17-027028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924317027028/doc4.xml","form_type":"4"}},{"id":4155935,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":1,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171724,"kind":"organization","name":"NeoMed Management (Jersey) Ltd","position":2,"cik":"0001722665","reported_name":"NeoMed Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":3,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T23:15:22.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":279079,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":567639,"source":{"system":"sec-edgar","filing":"0000899243-17-027028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924317027028/doc4.xml","form_type":"4"}},{"id":4155934,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":1,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171724,"kind":"organization","name":"NeoMed Management (Jersey) Ltd","position":2,"cik":"0001722665","reported_name":"NeoMed Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":3,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T23:15:22.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":41878,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":288560,"source":{"system":"sec-edgar","filing":"0000899243-17-027028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924317027028/doc4.xml","form_type":"4"}},{"id":4155933,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":1,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171724,"kind":"organization","name":"NeoMed Management (Jersey) Ltd","position":2,"cik":"0001722665","reported_name":"NeoMed Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":3,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T23:15:22.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":246682,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":246682,"source":{"system":"sec-edgar","filing":"0000899243-17-027028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924317027028/doc4.xml","form_type":"4"}}]}